Indicated for: type 2 diabetes mellitus
Substance: metformin + glibenclamide (biguanide antidiabetic + sulfonylurea antidiabetic)
ATC: A10BD02 (Alimentary tract and metabolism | Blood glucose lowering drugs, excl. insulins | Combinations of oral blood glucose lowering drugs)
The combination of metformin and glibenclamide is used to treat type 2 diabetes, particularly in patients for whom monotherapy with either metformin or glibenclamide is insufficient to control blood sugar levels. This combination leverages two different mechanisms of action to improve glycemic control.
Metformin belongs to the biguanide class and works by reducing glucose production in the liver, improving insulin sensitivity in cells, and decreasing glucose absorption in the intestines. It is considered the first-line treatment for type 2 diabetes due to its effectiveness and safety profile.
Glibenclamide is a sulfonylurea derivative that stimulates the pancreas to produce more insulin. This mechanism helps lower blood sugar levels, especially after meals, but requires the pancreas to be capable of producing insulin.
This combination is taken as tablets, usually once or twice daily with meals, to reduce the risk of gastrointestinal side effects. The dose is adjusted by the doctor based on blood sugar levels and the patient’s response to treatment.
Common side effects include nausea, diarrhea, abdominal pain, or hypoglycemia (low blood sugar). In rare cases, metformin can cause lactic acidosis, a serious condition requiring immediate medical attention. Glibenclamide may increase the risk of hypoglycemia, particularly in elderly patients or those who skip meals.
This combination is not recommended for patients with severe renal impairment, liver failure, heart failure, or other conditions that increase the risk of lactic acidosis. It is important for patients to follow a balanced diet, engage in regular physical activity, and frequently monitor their blood sugar levels.